Targeting Abnormal Cell Cycle in Cancer
A special issue of Onco (ISSN 2673-7523).
Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 5089
Special Issue Editors
Interests: oncogene; tumor suppressor; tumor metabolism; RB; Ras; RECK
Special Issues, Collections and Topics in MDPI journals
Interests: cell cycle; G1 progression; tumorigenesis; cancer metabolism; ROS regulation; leukemogenesis; lipid metabolism
Special Issue Information
Dear Colleagues,
A variety of oncogenic signals merge on the upregulation of D-type cyclins and, thus, many of the molecular targeting drugs attenuate abnormal cell proliferation by suppressing kinases whose function is dependent on cyclins. Synthetic CDK4/6 inhibitors exert antitumor effects by maintaining RB1 in an unphosphorylated state, causing cell cycle arrest in G1 phase, cellular senescence, apoptosis and increased immunogenicity. The successful result of breast cancer treatment by CDK4/6 inhibitors in combination with endocrine therapy has demonstrated that targeting the key machinery of cell cycle control bears significant clinical benefits. This Special Issue will highlight basic and clinical studies that aim to develop novel or improved therapeutic strategies targeting abnormal cell cycle in cancer.
Prof. Dr. Chiaki Takahashi
Prof. Dr. Jun-ya Kato
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Onco is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- RB
- CDK
- cancer therapy
- resistance
